Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy"
- PMID: 35176440
- DOI: 10.1016/j.jhep.2022.02.002
Reply to: "The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy"
Conflict of interest statement
Conflicts of interest B.S. received travel support from AbbVie, Ipsen and Gilead. MP is an investigator for Bayer, BMS, Eisai, Ipsen, Lilly, and Roche; he received speaker honoraria from Bayer, BMS, Eisai, Lilly, MSD, and Roche; he is a consultant for Bayer, BMS, Eisai, Ipsen, Lilly, MSD, and Roche; he received travel support from Bayer and BMS. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment on
-
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.J Hepatol. 2022 Feb;76(2):353-363. doi: 10.1016/j.jhep.2021.09.035. Epub 2021 Oct 12. J Hepatol. 2022. PMID: 34648895
-
The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.J Hepatol. 2022 May;76(5):1232-1233. doi: 10.1016/j.jhep.2021.12.033. Epub 2022 Jan 19. J Hepatol. 2022. PMID: 35063602 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical